| Name: | Afatinib Impurity E |
| Catalogue No. | VL5510008 |
| CAS No. | N/A |
| Molecular Formula | C24H25Cl2N5O3 |
| Molecular Weight | 502.4 |
| Status | Under Development |
| IUPAC Name | (S,Z)-N-(4-((3,4-dichlorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide |
| Description | Afatinib Impurity E(CAS No: N/A) or (S,Z)-N-(4-((3,4-dichlorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)-4-(dimethylamino)but-2-enamide,Afatinib Impurity E is an impurity of Afatinib, is an antineoplastic agent and 4-anilinoquinazoline tyrosine kinase inhibitor that is used to treat a certain type of lung cancer. |
| References | Ricciuti, Biagio, et al. “Afatinib in the First-Line Treatment of Patients with Non-Small Cell Lung Cancer: Clinical Evidence and Experience.” Therapeutic Advances in Respiratory Disease, vol. 12, 25 Oct. 2018, p. 1753466618808659, www.ncbi.nlm.nih.gov/pmc/articles/PMC6204616/, 10.1177/1753466618808659. |
